Splash Beverage Group Inc.(SBEV)宣布,已与一支经验丰富的 cannabinoid(大麻素)药物开发团队达成合作,共同推进其旗下产品 Cannepil® 进入美国食品药品监督管理局(FDA)的兽医审批流程。这一战略举措,旨在借助专业团队的深厚积淀,将 Cannepil® 从研发阶段推向监管认证的关键节点。
Splash Beverage Group Inc.(SBEV)宣布,已与一支经验丰富的 cannabinoid(大麻素)药物开发团队达成合作,共同推进其旗下产品 Cannepil® 进入美国食品药品监督管理局(FDA)的兽医审批流程。这一战略举措,旨在借助专业团队的深厚积淀,将 Cannepil® 从研发阶段推向监管认证的关键节点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.